YC Companies/Winter 2021/Valink Therapeutics
Valink Therapeutics logo

Valink Therapeutics

Discovering bispecific antibody drug-conjugates (BsADC) against cancer

Winter 2021Healthcare / Healthcare -> TherapeuticsBoston, MA, USA15 employees
Biotech
Therapeutics
Drug discovery

About

Valink Therapeutics develops next generation antibody-based therapeutics. We identify novel mechanism of action from known targets by incorporating multiple antibody modifications at once, rapidly and scalable generating complex drug candidates (bi-/multispecificity, multivalency and drug-conjugation in a single discovery process). Our research focus is on solid tumours poorly addressed by immunotherapy.

Founders (2)

Arne Scheu
Founder
Irsyad Khairil
Founder

Details

Status
Active
Stage
Early
Team Size
15
Regions
United States of America, America / Canada, Remote, Partly Remote